tradingkey.logo

TARA-002 Demonstrates 68% Complete Response Rate At Six Months In BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

ReutersFeb 23, 2026 10:28 PM

- Protara Therapeutics Inc TARA.O:

  • TARA-002 DEMONSTRATES 68% COMPLETE RESPONSE RATE AT SIX MONTHS IN BCG-UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER

  • PROTARA THERAPEUTICS INC: EXPECTS TO COMPLETE ENROLLMENT OF BCG-UNRESPONSIVE COHORT OF ADVANCED-2 TRIAL IN 2H 2026

  • PROTARA THERAPEUTICS INC: FAVORABLE SAFETY AND TOLERABILITY PROFILE WITH NO GRADE 3 OR GREATER TREATMENT-RELATED ADVERSE EVENTS

  • PROTARA THERAPEUTICS INC: REMAINS ON TRACK TO INITIATE ADVANCED-3 REGISTRATIONAL TRIAL IN BCG-NAÏVE PATIENTS IN SECOND HALF OF 2026

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI